Gilles Clapisson

28 Rue Laennec
Lyon, 69008, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients.

A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients.

Journal: BMC cancer
Published: August 31, 2017

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 04, 2017

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.

Journal: PLoS medicine
Published: October 04, 2016

Copper isotope effect in serum of cancer patients. A pilot study.

Copper isotope effect in serum of cancer patients. A pilot study.

Journal: Metallomics : integrated biometal science
Published: December 24, 2014

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 05, 2014

Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome.

Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome.

Journal: European journal of cancer (Oxford, England : 1990)
Published: October 25, 2012

CD4 lymphopenia to identify end-of-life metastatic cancer patients.

CD4 lymphopenia to identify end-of-life metastatic cancer patients.

Journal: European journal of cancer (Oxford, England : 1990)
Published: August 27, 2012

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.

Journal: Oncoimmunology
Published: July 04, 2012
Showing 1-8 of 8

Last Updated: 09/26/2026